Maternal consumption of fructo-oligosaccharide diminishes the severity of skin inflammation in offspring of NC/Nga mice.
Strategies to manipulate the gut microbiota in infancy have been considered to prevent the development of allergic diseases later in life. We aimed to elucidate the effects of maternal dietary supplementation with a prebiotic oligosaccharide on gut microbiota and spontaneously developing atopic dermatitis-like skin lesions in the offspring of NC/Nga mice. Female NC/Nga mice were fed diets either with or without fructo-oligosaccharide supplementation during pregnancy and lactation. After weaning, offspring were fed the diets supplemented with or without fructo-oligosaccharide for 11 weeks in an air-uncontrolled conventional room. Changes in gut microbiota were assessed by denaturing gradient gel electrophoresis of the PCR-amplified 16S rRNA gene. Skin lesions were evaluated by a clinical score and scratching behaviour. Serum antibody levels were measured by ELISA, and expression levels of cytokines and chemokines in lesional tissue were evaluated by quantitative RT-PCR. Maternal supplementation with fructo-oligosaccharide modulated the gut microbiota in sucklings. Although maternal supplementation with fructo-oligosaccharide suppressed the increase in clinical skin severity score and scratching behaviour in offspring, dietary fructo-oligosaccharide after weaning was less effective. The diminution of skin lesions was accompanied by lower serum concentrations of total IgG1 and lower expression levels of TNF-alpha in the lesional tissue. These data suggest that maternal consumption of fructo-oligosaccharide diminishes the severity of atopic dermatitis-like skin lesions in the offspring of NC/Nga mice.
Laboratory of Gastrointestinal Physiology, Graduate School of Life Science, Hokkaido University, Sapporo 060-8589, Japan.
Reiko
R
Fujiwara
Naoki
N
Takemura
Jun
J
Watanabe
Kei
K
Sonoyama
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D004040:Dietary Carbohydrates / Q000494:pharmacology / Q000627:therapeutic use; D019587:Dietary Supplements; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D041981:Gastrointestinal Tract / Q000382:microbiology*; D007074:Immunoglobulin G / Q000097:blood; D007774:Lactation; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009035:Mothers; D009844:Oligosaccharides / Q000494:pharmacology / Q000627:therapeutic use*; D056692:Prebiotics; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D012336:RNA, Ribosomal, 16S; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D004040:Dietary Carbohydrates; D007074:Immunoglobulin G; D009844:Oligosaccharides; D056692:Prebiotics; D012336:RNA, Ribosomal, 16S; D014409:Tumor Necrosis Factor-alpha; C098616:fructo-oligosaccharide-shitake